Some endocrinologists are prescribing a cautious attitude toward FDA’s recent warning on the link between SGLT2 inhibitors and diabetic ketoacidosis in type 2 diabetes until more details are available about the cases reported.
FDA issued a safety announcement on May 15 noting that 20 cases of diabetic acidosis, including diabetic ketoacidosis (DKA), ketoacidosis...